Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies

Ralph N Martins^{1

2

3

4

5}, Victor Villemagne^{6

7}, Hamid R Sohrabi^{1

2

3

4

5

8}, Pratishtha Chatterjee^{1

3

5}, Tejal M Shah^{1

2

3}, Giuseppe Verdile^{1

2

9}, Paul Fraser¹⁰, Kevin Taddei^{1

2

8}, Veer B Gupta^{1

8}, Stephanie R Rainey-Smith^{1

2}, Eugene Hone^{1

8}, Steve Pedrini^{1

8}, Wei Ling Lim¹, Ian Martins¹, Shaun Frost¹¹, Sunil Gupta^{1

2

3

5}, Sid O'Bryant¹², Alan Rembach⁷, David Ames^{13

14}, Kathryn Ellis¹⁵, Stephanie J Fuller², Belinda Brown^{2

16}, Samantha L Gardener^{1

2}, Binosha Fernando¹, Prashant Bharadwaj¹, Samantha Burnham^{1

17}, Simon M Laws^{1

8

18}, Anna M Barron^{4

19}, Kathryn Goozee^{3

4

5

20

8}, Eka J Wahjoepramono¹, Prita R Asih^{5

21}, James D Doecke²², Olivier Salvado^{22

8}, Ashley I Bush^{7

8}, Christopher C Rowe^{6

7}, Samuel E Gandy²³, Colin L Masters⁸

Affiliations

¹ Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
² Australian Alzheimer's Research Foundation, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, WA, Australia.
³ Department of Biomedical Sciences, Macquarie University, Sydney, NSW, Australia.
⁴ School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth WA, Australia.
⁵ KaRa Institute of Neurological Diseases, Sydney NSW, Australia.
⁶ Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia.
⁷ Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
⁸ Cooperative Research Centre for Mental Health, Carlton, VIC, Australia.
⁹ School of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University of Technology, Bentley, WA, Australia.
¹⁰ Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, ON, Canada.
¹¹ CSIRO Australian e-Health Research Centre/Health and Biosecurity, Perth, WA, Australia.
¹² University of North Texas Health Science Centre, Fort Worth, TX, USA.
¹³ National Ageing Research Institute, Parkville, VIC, Australia.
¹⁴ University of Melbourne Academic Unit for Psychiatry of Old Age, St George's Hospital, Kew, VIC, Australia.
¹⁵ Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia.
¹⁶ School of Psychology and Exercise Science, Murdoch University, Perth, WA, Australia.
¹⁷ eHealth, CSIRO Health and Biosecurity, Parkville, VIC, Australia.
¹⁸ Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.
¹⁹ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
²⁰ Anglicare, Sydney, NSW, Australia.
²¹ School of Medical Sciences, University of New South Wales, Kensington, NSW, Australia.
²² CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia.
²³ Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

PMID: 29562546
PMCID: PMC5870031
DOI: 10.3233/JAD-171145

Review

Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies

Ralph N Martins et al. J Alzheimers Dis. 2018.

. 2018;62(3):965-992.

doi: 10.3233/JAD-171145.

Authors

Affiliations

¹ Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
² Australian Alzheimer's Research Foundation, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, WA, Australia.
³ Department of Biomedical Sciences, Macquarie University, Sydney, NSW, Australia.
⁴ School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth WA, Australia.
⁵ KaRa Institute of Neurological Diseases, Sydney NSW, Australia.
⁶ Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia.
⁷ Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
⁸ Cooperative Research Centre for Mental Health, Carlton, VIC, Australia.
⁹ School of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University of Technology, Bentley, WA, Australia.
¹⁰ Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, ON, Canada.
¹¹ CSIRO Australian e-Health Research Centre/Health and Biosecurity, Perth, WA, Australia.
¹² University of North Texas Health Science Centre, Fort Worth, TX, USA.
¹³ National Ageing Research Institute, Parkville, VIC, Australia.
¹⁴ University of Melbourne Academic Unit for Psychiatry of Old Age, St George's Hospital, Kew, VIC, Australia.
¹⁵ Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia.
¹⁶ School of Psychology and Exercise Science, Murdoch University, Perth, WA, Australia.
¹⁷ eHealth, CSIRO Health and Biosecurity, Parkville, VIC, Australia.
¹⁸ Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.
¹⁹ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
²⁰ Anglicare, Sydney, NSW, Australia.
²¹ School of Medical Sciences, University of New South Wales, Kensington, NSW, Australia.
²² CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia.
²³ Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

PMID: 29562546
PMCID: PMC5870031
DOI: 10.3233/JAD-171145

Abstract

Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the Aβ peptide in Alzheimer's disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye. The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years. AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E ɛ4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral Aβ.

Keywords: Alzheimer’s disease; Aβ; amyloid; apolipoprotein E; biomarker; dementia; early diagnosis; preclinical.

PubMed Disclaimer

References

1. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83, 4913–4917. - PMC - PubMed
1. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261, 6084–6089. - PubMed
1. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K (1985) Neuronal origin of a cerebral amyloid: Neurofibrillary tangles of Alzheimer’s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 4, 2757–2763. - PMC - PubMed
1. Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, Beyreuther K, Masters CL (1988) A4 amyloid protein deposition and the diagnosis of Alzheimer’s disease: Prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38, 1688–1693. - PubMed
1. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82, 4245–4249. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies

Affiliations

Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical